A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

James Chih‐Hsin Yang, Leah Haworth, Richard M. Sherry et al. · New England Journal of Medicine · 2003 · 2.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

David F. McDermott, Meredith M. Regan, Joseph I. Clark et al. · Journal of Clinical Oncology · 2004 · 819 citations

Medicine, Oncology, Pharmacotherapy +15

Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Jennifer Bacik, Lawrence H. Schwartz et al. · Journal of Clinical Oncology · 2004 · 803 citations

Medicine, Biostatistics, Oncology +16

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Victor Sandor, Susan Bakke, Robert W. Robey et al. · PubMed · 2002 · 510 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +12